Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Research & Development (2016 - 2026)

Amphastar Pharmaceuticals has reported Research & Development over the past 13 years, most recently at $23.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 28.51% year-over-year to $23.3 million; the TTM value through Dec 2025 reached $85.8 million, up 16.14%, while the annual FY2025 figure was $85.8 million, 16.14% up from the prior year.
  • Research & Development for Q4 2025 was $23.3 million at Amphastar Pharmaceuticals, up from $22.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $23.3 million in Q4 2025 and troughed at $10.8 million in Q3 2021.
  • A 5-year average of $18.5 million and a median of $18.1 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: crashed 39.02% in 2021 and later soared 72.08% in 2022.
  • Year by year, Research & Development stood at $17.3 million in 2021, then decreased by 0.29% to $17.2 million in 2022, then rose by 18.47% to $20.4 million in 2023, then fell by 11.15% to $18.1 million in 2024, then rose by 28.51% to $23.3 million in 2025.
  • Business Quant data shows Research & Development for AMPH at $23.3 million in Q4 2025, $22.4 million in Q3 2025, and $20.1 million in Q2 2025.